Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China)

Cancer Epidemiology

Volumn 38, Issue 6, 2014, Pages 748-756

  Serrano, Beatriz ^a   Alemany, Laia ^a,b   Ruiz, Patricia Alonso de ^c   Tous, Sara ^a   Lima, Marcus Aurelho ^d   Bruni, Laia ^a   Jain, Asha ^e   Clifford, Gary M ^f   Qiao, You Lin ^g   Weiss, Thomas ^h   Bosch, F Xavier ^a   de Sanjosé, Silvia ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d Hospital Dr Helio Angotti   (Brazil)

^e Cancer Prevention and Relief Society   (India)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g PEKING UNION MEDICAL COLLEGE   (China)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Brazil; China; Epidemiology; Genotype; Human papillomavirus; Human papillomavirus vaccines; India; Mexico; Uterine cervical neoplasms

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; BRAZIL; CANCER CONTROL; CANCER PREVENTION; CHINA; CROSS-SECTIONAL STUDY; CYTODIAGNOSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; INDIA; INVASIVE CERVICAL CANCER; MAJOR CLINICAL STUDY; MEXICO; PAPILLOMAVIRUS INFECTION; PRECANCER; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER; CLINICAL TRIAL; GENOTYPE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRIDAE; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

BRAZIL; CHINA; FEMALE; GENOTYPE; HUMANS; INDIA; MEXICO; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84912521882     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2014.09.003     Document Type: Article

References (43)

1. World Development Indicators Database, 2013. Washington, DC, World Bank. Available at: [Accessed on December 2013]. http://databank.worldbank.org/data/download/GDP_PPP.pdf.
2. Goldman Sachs Annual Report 2003 Available at: [Accessed on December 2013]. http://www.goldmansachs.com/investor-relations/financials/archived/annual-reports/attachments/2003-annual-report.pdf.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
4. IARC Monographs on the evaluation of carcinogenic risks to humans. A Review of Human Carcinogens. Part B: Biological Agents 2011, Vol 100. International Agency for Research on Cancer, Lyon, France.
5. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] 2013, International Agency for Research on Cancer, Lyon, France, Available at: http://globocan.iarc.fr [Accessed on December 2013].
6. Soerjomataram I., Lortet-Tieulent J., Parkin D.M., Ferlay J., Mathers C., Forman D., et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012, 380(9856):1840-1850.
7. World Health Organization (WHO) Human papillomavirus vaccines WHO position paper 2009, World Health Organization, Geneva, Available at: http://www.who.int/wer/2009/wer8415.pdf [Accessed on December 2013].
8. De Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
9. Li N., Franceschi S., Howell-Jones R., Snijders P.J.F., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128(4):927-935.
10. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199(6):805-814.
11. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011, 7(2):161-169.
12. Schiller J.T., Castellsagué X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl 5):F123-F138.
13. PATH - Global HPV vaccine licensure status: June 2011 Available at: [Accessed on December 2013]. http://www.technet-21.org/resources/documents/doc_download/1286-global-hpv-vaccine-licensure-status-june-2011.
14. Annual WHO/UNICEF Joint Reporting Form and WHO Regional offices reports (Update of 2013/October/03). Geneva, Immunization, Vaccines and Biologicals (IVB), World Health Organization. Available at: [Accessed on December 2013]. http://www.who.int/immunization_monitoring/data/data_subject/en/index.html.
15. Markowitz L.E., Tsu V., Deeks S.L., Cubie H., Wang S.A., Vicari A.S., et al. Human papillomavirus vaccine introduction--the first five years. Vaccine 2012, 30(Suppl 5):F139-F148.
16. Goldie S.J., O'Shea M., Diaz M., Kim S.-Y. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008, 16(32):86-96.
17. Brotherton J.M.L., Gertig D.M. Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Rev Anti Infect Ther 2011, 9(8):627-639.
18. Joura E, on behalf of the V503-001 study team. Immunogenicity of a novel 9-valent HPV L1 Virus-Like Particle Vaccine in 16 to 26-year-old women, Florence, November 3-6, Eurogin 2013. SS 8-4. p. 102.
19. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjosé S., Franceschi S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131(10):2349-2359.
20. Insinga R.P., Liaw K.-L., Johnson L.G., Madeleine M.M. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomark Prev 2008, 17(7):1611-1622.
21. Wentzensen N., Schiffman M., Dunn T., Zuna R.E., Gold M.A., Allen R.A., et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009, 125(9):2151-2158.
22. United Nations, Department of Economic, Social Affairs, Population Division World Population prospects: the 2012 revision. 2013, Available at: http://esa.un.org/wpp/unpp/panel_population.htm [Accessed on December 2013].
23. Zhang H.-Y., Tiggelaar S.M., Sahasrabuddhe V.V., Smith J.S., Jiang C.-Q., Mei R.-B., et al. HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study. Asian Pac J Cancer Prev 2012, 13(1):91-96.
24. Li H., Zhang J., Chen Z., Zhou B., Tan Y. Prevalence of human papillomavirus genotypes among women in Hunan province, China. Eur J Obstet Gynecol Reprod Biol 2013, 170(1):202-205.
25. Chan P.K. Human papillomavirus type 58: the unique role in cervical cancers in East Asia. Cell Biosci 2012, 2(1):17.
26. Oliveira C.M., de, Fregnani J.H.T.G., Carvalho J.P., Longatto-Filho A., Levi J.E. Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil. BMC Cancer 2013, 13(1):357.
27. Peralta-Rodríguez R., Romero-Morelos P., Villegas-Ruíz V., Mendoza-Rodríguez M., Taniguchi-Ponciano K., González-Yebra B., et al. Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis. Infect Agent Cancer 2012, 7(1):34.
28. Basu P., Roychowdhury S., Bafna U.D., Chaudhury S., Kothari S., Sekhon R., et al. Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac J Cancer Prev 2009, 10(1):27-34.
29. Sankaranarayanan R., Bhatla N., Gravitt P.E., Basu P., Esmy P.O., Ashrafunnessa K.S., et al. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. Vaccine 2008, 26(Suppl 12):M43-M52.
30. Deodhar K., Gheit T., Vaccarella S., Romao C.C., Tenet V., Nene B.M., et al. Prevalence of human papillomavirus types in cervical lesions from women in rural Western India. J Med Virol 2012, 84(7):1054-1060.
31. Chen W., Zhang X., Molijn A., Jenkins D., Shi J.-F., Quint W., et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009, 20(9):1705-1713.
32. Clifford G., Franceschi S. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008, 122(7):1684-1685.
33. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907.
34. Bosch F.X., Broker T.R., Forman D., Moscicki A.-B., Gillison M.L., Doorbar J., et al. Comprehensive control of human Papillomavirus infections and related diseases. Vaccine 2013, 31(Suppl 8):I1-I31.
35. Canfell K., Shi J.-F., Lew J.-B., Walker R., Zhao F.-H., Simonella L., et al. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 2011, 29(13):2487-2494.
36. Wu E.-Q., Liu B., Cui J.-F., Chen W., Wang J.-B., Lu L., et al. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study. Cancer Causes Control 2013, 24(4):795-803.
37. Lazcano-Ponce E.C., Moss S., Alonso de Ruíz P., Salmerón Castro J., Hernández Avila M. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Arch Med Res 1999, 30(3):240-250.
38. Murillo R., Almonte M., Pereira A., Ferrer E., Gamboa O.A., Jerónimo J., et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008, 26(Suppl 11):L37-L48.
39. Villa L.L. Cervical cancer in Latin America and the Caribbean: the problem and the way to solutions. Cancer Epidemiol Biomarkers Prev 2012, 21(9):1409-1413.
40. Vizcaino A.P., Moreno V., Bosch F.X., Muñoz N., Barros-Dios X.M., Parkin D.M. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998, 75(4):536-545.
41. Alemany L., de Sanjosé S., Tous S., Quint W., Vallejos C., Shin H.R., RIS HPV TT Study Group, et al. Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int J Cancer 2014, 135(1):88-95.
42. De Vuyst H., Alemany L., Lacey C., Chibwesha C.J., Sahasrabuddhe V., Banura C., Denny L., Parham G.P. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine 2013, 31(Suppl 5):F32-F46.
43. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., Bosch F.X., deSanjosé S. Potential impact of a nine-valent vaccine in human papilloma virus related cervical disease. Infect Agent Cancer 2012 Dec 29, 7(1):38.